targetedonc.com Breaking News Headlines Today | Ground News

targetedonc.com image

News from targetedonc.com

See all of targetedonc.com’s headline news. Compare how the top news stories are covered by left-wing and right-wing news sources.

We’ve aggregated 579 of targetedonc.com’s headlines and news stories over the past 3 months.

Ground News rates targetedonc.com’s media bias as . . Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check.

Is targetedonc.com credible or reliable? Our Factuality score answers both of those questions. When it comes to targetedonc.com, we’ve assigned a Unknown factuality rating. Ratings are assigned by aggregating scores from Ad Fontes Media and Media Bias/Fact Check.

Information about targetedonc.com

Where is targetedonc.com located?targetedonc.com's Website

Media Bias Ratings

Do you diasgree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top targetedonc.com News

FDA Approves Checkpoint Therapeutics' Skin Cancer Drug One Year After Rejection - Checkpoint Therapeutics (NASDAQ:CKPT)

FDA · United States

FDA Approves Checkpoint Therapeutics' Skin Cancer Drug One Year After Rejection - Checkpoint Therapeutics (NASDAQ:CKPT)

100% Center coverage: 3 sources

On Friday, the FDA approved Checkpoint Therapeutics, Inc.’s (NASDAQ:CKPT) Unloxcyt (cosibelimab-ipdl) for metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC who are not candidates for curative surgery or curative radiation. Unloxcyt is the first and only programmed death ligand-1 (PD-L1) blocking antibody to receive FDA marketing approval for this indication. The recommended commercial dosage of Unloxcyt is 1,200 mg adm…See the Story

Decade of research by Birmingham doctor will improve lives of cancer patients

Decade of research by Birmingham doctor will improve lives of cancer patients

Coverage: 2 sources

Academic research which could help transform the lives of people with cancer will be shared across Europe thanks to specialist head and neck charity Get A-Head.See the Story

Mesoblast's RYONCIL Makes History: First MSC Therapy FDA-Approved with 70% Response Rate in Critical Child Disease

History · United States

Mesoblast's RYONCIL Makes History: First MSC Therapy FDA-Approved with 70% Response Rate in Critical Child Disease

Breakthrough therapy RYONCIL receives historic FDA approval for treating steroid-resistant GvHD in children, showing remarkable 70% response rate in clinical trials.See the Story

Latest News Stories

You've scrolled to the bottom of the feed, there are no more stories.

Donate Privacy Policy Manage Cookies Terms and Conditions

© 2024 Snapwise Inc